Company news

MannKind Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18

June 27, 2021

MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29

June 24, 2021

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

June 15, 2021

MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA

June 15, 2021

MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases

June 9, 2021

MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference

June 7, 2021

MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5

June 2, 2021

MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly

May 12, 2021

MannKind Corporation Reports 2021 First Quarter Financial Results

May 11, 2021

MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference

May 10, 2021

MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021

May 4, 2021

MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche

April 25, 2021

Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA

April 18, 2021

MannKind Announces Closing of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes

March 15, 2021

MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors

March 14, 2021

MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference

March 9, 2021

MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference

March 1, 2021

MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering

March 1, 2021

MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes

February 28, 2021

MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results

February 24, 2021

MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference

February 17, 2021

MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021

February 17, 2021

MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference

January 3, 2021

MannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium) Oral Solution

December 16, 2020

James S. Shannon Transitions to Chairman of the Board of Directors for MannKind

December 9, 2020

MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.

December 6, 2020

MannKind and MidCap Amend Credit Facility

November 30, 2020

Sabrina Kay Appointed to MannKind Board of Directors

November 29, 2020

MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics

November 18, 2020

MannKind Corporation Reports 2020 Third Quarter Financial Results

November 3, 2020

MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020

October 28, 2020

Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety

August 30, 2020

MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020

August 6, 2020

MannKind Corporation Reports 2020 Second Quarter Financial Results

August 4, 2020

MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020

July 28, 2020

Alejandro Galindo Joins MannKind as Chief Commercial Officer

July 19, 2020

MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference

June 16, 2020

MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions

June 14, 2020

Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM

June 12, 2020

MannKind Corporation Reports 2020 First Quarter Financial Results

May 5, 2020

MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020

April 28, 2020

MannKind Receives Forgivable Loan under the Paycheck Protection Program

April 14, 2020

Jennifer Grancio Appointed to MannKind Board of Directors

March 23, 2020

MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic

March 16, 2020

MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results

February 24, 2020

MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 23, 2020

MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)

February 19, 2020

MannKind Corporation to Hold 2019 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2020

February 17, 2020

Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month

January 5, 2020

Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes

December 19, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.